Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9423167 | Brain Research Reviews | 2005 | 6 Pages |
Abstract
Previously, we and others demonstrated that PPAR-γ agonists including 15d-PGJ2 are effective in the treatment of experimental autoimmune encephalomyelitis (EAE), an animal model of MS. PPAR-γ modulation of EAE may occur, at least in part, by inhibition of microglial cell activation. Here, we indicate that 15d-PGJ2 is a more potent inhibitor of microglial activation than thiazolidinediones, which are currently used to treat diabetes. Furthermore, 15d-PGJ2 acts cooperatively with 9-cis retinoic acid, the ligand for the retinoid X receptor (RXR), in inhibiting microglial cell activation. This suggests that 15d-PGJ2 and 9-cis RA inhibit cell activation through the formation of PPAR-γ/RXR heterodimers. Interestingly, PGA2, which like 15d-PGJ2 is a cyclopentenone prostaglandin, but which unlike 15d-PGJ2 does not bind PPAR-γ, is a potent inhibitor of microglial cell activation. Collectively, these studies suggest that 15d-PGJ2 inhibits microglial cell activation by PPAR-γ-dependent as well as PPAR-γ-independent mechanisms. The studies further suggest that the PPAR-γ agonist 15d-PGJ2 in combination with retinoids may be effective in the treatment of MS.
Keywords
Related Topics
Life Sciences
Neuroscience
Neuroscience (General)
Authors
Paul D. Drew, Paul D. Storer, Jihong Xu, Janet A. Chavis,